Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ASPH | Q12797 | 1/20 | 0.41 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.41 |
| ▸ | TPMT | P51580 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19866316 | 0.88 | TP53 (0.41) | KEAP1NFE2L2TTRKDM4EASPH | |
| SCHEMBL18713921 | 0.84 | KEAP1 (0.44) | KEAP1NFE2L2TTRKDM4EASPH | |
| SCHEMBL2371151 | 0.83 | KCNK2 (0.43) | KEAP1NFE2L2TTRKDM4EASPH | |
| SCHEMBL16277463 | 0.83 | KEAP1 (0.40) | KEAP1NFE2L2TTRKDM4EASPH | |
| SCHEMBL16277410 | 0.83 | KDM4E (0.40) | KEAP1NFE2L2TTRKDM4EASPH | |
| SCHEMBL24746193 | 0.83 | TTR (0.41) | KEAP1NFE2L2TTRKDM4EASPH | |
| SCHEMBL1685590 | 0.82 | TPMT (0.48) | KDM4ETPMTAKR1C2AKR1C1ALDH1A1 | |
| SCHEMBL4830274 | 0.82 | KEAP1 (0.54) | KEAP1NFE2L2TTRKDM4EASPH | |
| SCHEMBL3870844 | 0.81 | KEAP1 (0.45) | KEAP1NFE2L2TTRKDM4EASPH | |
| SCHEMBL34467596 | 0.79 | TPMT (0.46) | KDM4ETPMTALDH1A1ALOX15CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396159-A | Synthesis method of 2,2' -biphenyl dicarboxylic acid compound | 湖南大学 | 2023-07-07 | — | — | CN | claimed |
| WO-2025224759-A1 | INDANOL SUBSTITUTED DIAMINO PYRIMIDINE CARBOXAMIDES AS DUAL ATM/DNA-PK INHIBITORS | BUGWORKS RESEARCH INDIA PVT. LTD (IN) | 2025-10-30 | — | — | WO | disclosed |
| EP-4626427-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND A BCL-2 INHIBITOR | Janssen Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4626426-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND AT LEAST ONE OTHER THERAPEUTIC AGENT | JANSSEN Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| US-20250302840-A1 | COMBINATION THERAPIES | JANSSEN-CILAG (FR) | 2025-10-02 | — | — | US | disclosed |
| CN-119143691-B | Thiadiazole derivative and preparation method and application thereof | 山东大学日照研究院 | 2025-06-24 | — | — | CN | disclosed |
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| CN-119143691-A | Thiadiazole derivative and preparation method and application thereof | 山东大学日照研究院 | 2024-12-17 | — | — | CN | disclosed |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | ATLASMEDX, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118910629-A | Electrochemical synthesis method of quinazolinone derivative | 齐齐哈尔医学院 | 2024-11-08 | — | — | CN | disclosed |
| US-9499517-B2 | Substituted prolines / piperidines as orexin receptor antagonists | EOLAS THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9440982-B2 | Substituted prolines/piperidines as orexin receptor antagonists | EOLAS THERAPEUTICS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| WO-2015123355-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | EOLAS THERAPEUTICS, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
| US-20140364432-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-11 | — | — | US | disclosed |
| US-20140364433-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-11 | — | — | US | disclosed |
| WO-2004073612-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO. INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-0370686-B1 | A process for preparing quinolone carboxylic acid intermediates | PFIZER (US) | 1993-12-29 | — | — | EP | disclosed |
| US-5064958-A | CHEMICAL INTERMEDIATES FOR ANTIBACTERIAL COMPOUNDS | PFIZER INC. (US) | 1991-11-12 | — | — | US | disclosed |
| US-4939290-A | Bactericides | PFIZER INC. (US) | 1990-07-03 | — | — | US | disclosed |
| EP-0370686-A2 | A process for preparing quinolone carboxylic acid intermediates | PFIZER INC. (US) | 1990-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364433-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OPRL1 | KEAP1 2754/4885NFE2L2 1507/4885TTR 4444/4885 |
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | KEAP1 1099/4885NFE2L2 326/4885TTR 3630/4885 |
| US-20250302840-A1 | COMBINATION THERAPIES | MEN1, MLLT1, BMI1 | KEAP1 1091/4885NFE2L2 1209/4885TTR 1858/4885 |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | KEAP1 486/4885NFE2L2 146/4885TTR 4549/4885 |
| US-20140364432-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OPRL1 | KEAP1 2754/4885NFE2L2 1507/4885TTR 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.